By Michael Erman and Puyaan Singh July 15 (Reuters) – Johnson & Johnson said on Wednesday that its medical device unit underperformed in the second-quarter, even as strong sales of Tremfya for
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)